{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:58:09Z","timestamp":1791313089721,"version":"4.3.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201610FDN-375939-FDN-CDAA-171854"],"award-info":[{"award-number":["201610FDN-375939-FDN-CDAA-171854"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["Kidney Health Research Grant # 854079"],"award-info":[{"award-number":["Kidney Health Research Grant # 854079"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Potassium regulation in the body is primarily done in the kidney. In addition to this, hyperkalemia, occurs in approximately 10% of individuals with chronic kidney disease (CKD) and is associated with elevated all-cause mortality. Individuals with CKD are often told to restrict dietary potassium (K), however, this recommendation is based on low quality evidence. Reduced quality of life, limited dietary choices and nutritional deficiencies are all potential negative outcomes that may occur when restricting dietary K in CKD patients. There is a need for randomized controlled trials investigating the impact of dietary K modification on serum K concentrations in people with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized 2-period crossover design comparing a liberalized K fruit and vegetable diet where participants will be required to consume\u2009~\u20093500\u00a0mg of dietary K daily, to a standard K restricted diet where participants will be required to consume\u2009&lt;\u20092000\u00a0mg of dietary K daily. All participants will begin on a liberalized K run-in period for 2 weeks where they will receive fruit and vegetables home deliveries and for safety will have clinical chemistry, including serum potassium measurements taken after 1 week. Participants will then be randomized into either liberalized K or standard K diet for six weeks and then crossover to the other intervention for another 6 weeks after a 2-week washout period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      30 male and female CKD outpatients, \u2265\u200918 years of age, who have an estimated glomerular filtration rate (eGFR) between 15 and 45 ml\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      and serum K between 4.5 and 5.5 mEq\/L. This design would have greater than 80% power to detect a difference of 0.35 mEq\/L serum K between groups. Anthropometric measurements, clinical chemistry, dietary recalls, physical function assessments, as well as a quality of life assessments will also be measured in this trial. These findings will provide high quality evidence for, or against, recommendations for dietary K restriction in individuals living with CKD. The removal of K restriction could provide individuals living with CKD more dietary choice leading to improved dietary status and quality of life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>This trial has received approval from the University of Manitoba Research Ethics board (HS25191 (B2021:104)).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03354-4","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:02:07Z","timestamp":1697198527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dietary potassium liberalization with fruit and vegetables versus potassium restriction in people with chronic kidney disease (DK-Lib CKD): a clinical trial protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Yasmin","family":"Iman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Balshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Alexiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hingwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"7","key":"3354_CR1","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease \u2013 A systematic review and Meta-analysis. PLoS ONE. 2016;11(7):e0158765. https:\/\/doi.org\/10.1371\/journal.pone.0158765.","journal-title":"PLoS ONE"},{"issue":"9","key":"3354_CR2","doi-asserted-by":"publisher","first-page":"E417","DOI":"10.1503\/cmaj.120833","volume":"185","author":"P Arora","year":"2013","unstructured":"Arora P, Vasa P, Brenner D, et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ. 2013;185(9):E417\u201323. https:\/\/doi.org\/10.1503\/cmaj.120833.","journal-title":"CMAJ"},{"issue":"10225","key":"3354_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3.","journal-title":"Lancet"},{"key":"3354_CR4","unstructured":"Mantilla SJL. Impact of ACEi\/ARB Discontinuation after an Episode of Hyperkalemia in Patients with Chronic Kidney Disease. A Population-Based Cohort Study. MSc. University of Manitoba; 2020. https:\/\/mspace.lib.umanitoba.ca\/server\/api\/core\/bitstreams\/1e4e7385364f-4707-a9cf-38000c528b67\/content."},{"issue":"3","key":"3354_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.12990820","volume":"16","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Talarico R, Tangri N, et al. Ambulatory treatments for RAAS inhibitor\u2013related hyperkalemia and the 1-Year risk of recurrence. Clin J Am Soc Nephrol. 2021;16(3):365\u201373. https:\/\/doi.org\/10.2215\/CJN.12990820.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3354_CR6","unstructured":"American Kidney Fund. Health problems caused by kidney disease. KidneyFund.org. Accessed July 25., 2023. https:\/\/www.kidneyfund.org\/living-kidney-disease\/health-problems-caused-kidney-disease."},{"issue":"17","key":"3354_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","volume":"39","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Matsushita K, Sang Y, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehy100.","journal-title":"Eur Heart J"},{"issue":"8","key":"3354_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","volume":"179","author":"JA Noel","year":"2019","unstructured":"Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events Associated with Sodium Polystyrene Sulfonate Use in patients of Advanced Age. JAMA Intern Med. 2019;179(8):1025\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0631.","journal-title":"JAMA Intern Med"},{"key":"3354_CR9","unstructured":"Canada\u2019s Drug and Health Technology Agency. Sodium Zirconium Cyclosilicate (Lokelma). cadth.ca. Published May 14., 2020. Accessed July 25, 2023. https:\/\/www.cadth.ca\/sodium-zirconium-cyclosilicate."},{"issue":"4","key":"3354_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.jrn.2019.09.009","volume":"30","author":"A Morris","year":"2020","unstructured":"Morris A, Krishnan N, Kimani PK, Lycett D. Effect of Dietary Potassium Restriction on serum potassium, Disease Progression, and mortality in chronic kidney disease: a systematic review and Meta-analysis. J Ren Nutr. 2020;30(4):276\u201385. https:\/\/doi.org\/10.1053\/j.jrn.2019.09.009.","journal-title":"J Ren Nutr"},{"issue":"4","key":"3354_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3945\/an.112.002154","volume":"3","author":"JL Slavin","year":"2012","unstructured":"Slavin JL, Lloyd B. Health benefits of fruits and vegetables. Adv Nutr. 2012;3(4):506\u201316. https:\/\/doi.org\/10.3945\/an.112.002154.","journal-title":"Adv Nutr"},{"issue":"2","key":"3354_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.ajkd.2010.03.022","volume":"56","author":"N Noori","year":"2010","unstructured":"Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56(2):338\u201347. https:\/\/doi.org\/10.1053\/j.ajkd.2010.03.022.","journal-title":"Am J Kidney Dis"},{"issue":"S3","key":"3354_CR13","doi-asserted-by":"publisher","first-page":"206S","DOI":"10.1016\/S0895-7061(01)02090-8","volume":"14","author":"DA McCarron","year":"2001","unstructured":"McCarron DA, Reusser ME. Are low intakes of calcium and potassium important causes of cardiovascular disease? Am J Hypertens. 2001;14(S3):206S\u201312. https:\/\/doi.org\/10.1016\/S0895-7061(01)02090-8.","journal-title":"Am J Hypertens"},{"issue":"2","key":"3354_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on serum potassium level in patients with Hyperkalemia and Diabetic kidney disease: the AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314(2):151\u201361. https:\/\/doi.org\/10.1001\/jama.2015.7446.","journal-title":"JAMA"},{"key":"3354_CR15","doi-asserted-by":"publisher","first-page":"m824","DOI":"10.1136\/bmj.m824","volume":"369","author":"M Marklund","year":"2020","unstructured":"Marklund M, Singh G, Greer R, et al. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study. BMJ. 2020;369:m824. https:\/\/doi.org\/10.1136\/bmj.m824.","journal-title":"BMJ"},{"key":"3354_CR16","doi-asserted-by":"publisher","first-page":"205435812311901","DOI":"10.1177\/20543581231190180","volume":"10","author":"R Mollard","year":"2023","unstructured":"Mollard R, Cachero K, Luhovyy B, et al. Reducing Dietary Acid with Fruit and vegetables versus oral Alkali in people with chronic kidney disease (ReDACKD): a Clinical Research Protocol. Can J Kidney Health Dis. 2023;10:20543581231190180. https:\/\/doi.org\/10.1177\/20543581231190180.","journal-title":"Can J Kidney Health Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03354-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03354-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:16:21Z","timestamp":1700309781000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03354-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3354"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03354-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3207495\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the University of Manitoba Health Biomedical Research Ethics Board (HS25191 (B2021:104)) and is registered at clinicaltrials.gov (NCT05090865). All methods will be carried out in accordance to the Declaration of Helsinki. Additionally, the Priniciple Investigator and Quality Investigator of the trial will continue to ensure this happens throughout the duration of the trial. Lastly, informed consent will be taken from all subjects and\/or their legal guardians that want to participate in the study. This will be done by the study coordinator and\/or students who are GCP certified and have received the appropriate training on how to take informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; this is a study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}